Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer
incidence and mortality rates differ substantially across the world, reflecting varying patterns …

Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

Cancer of unknown primary (CUP) is a type of cancer that cannot be traced back to its
primary site and accounts for 3–5% of all cancers. Established targeted therapies are …

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …

Adenocarcinoma has become the most prevalent lung cancer sub-type and its frequency is
increasing. The earliest stages in the development of lung adenocarcinomas are visible …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Brain metastases from lung adenocarcinoma (BM-LUAD) frequently cause patient mortality.
To identify genomic alterations that promote brain metastases, we performed whole-exome …

While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Most EGFR exon 20 insertion (EGFR ex20ins) driver mutations in non–small cell lung
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …